Ownership Submission
|
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
OMB APPROVAL
|
|
OMB Number:3235-0104Expires:January 31, 2005Estimated average burden hours per response...0.5
|
|
|
1. Name and Address of Reporting Person *
|
|
Harler Mary Beth
|
|
2. Date of Event Requiring Statement (Month/Day/Year)
2024-04-14
|
3. Issuer Name and Ticker or Trading Symbol
IGM Biosciences, Inc. [IGMS]
|
|
(Last)
|
(First)
|
(Middle)
|
|
C/O IGM BIOSCIENCES, INC. , 325 E. MIDDLEFIELD ROAD
|
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
_____ Director
|
_____ 10% Owner
|
|
_____ Officer (give title below)
|
_____ Other (specify below)
|
|
Head, Research & Autoimmunity /
|
|
5. If Amendment, Date Original Filed(Month/Day/Year)
|
(Street)
|
|
MOUNTAIN VIEW
|
CA
|
94043
|
|
6. Individual or Join/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
|
|
Table I - Non-Derivative Securities Beneficially Owned
|
|
|
1.Title of Security
|
2. Amount of Securities Beneficially Owned
|
3. Ownership Form: Direct (D) or Indirect (I)
|
4. Nature of Indirect Beneficial Ownership
|
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
|
2. Date Exercisable and Expiration Date
|
3. Title and Amount of Securities Underlying Derivative Security
|
4. Conversion or Exercise Price of Derivative Security
|
5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
|
6. Nature of Indirect Beneficial Ownership
|
|
Date Exercisable
|
Expriation Date
|
Title
|
Amount or Number of Shares
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
|
Director
|
10% Owner
|
Officer
|
Other
|
Harler Mary Beth
C/O IGM BIOSCIENCES, INC.
325 E. MIDDLEFIELD ROAD
MOUNTAIN VIEW, CA94043
|
|
|
Head, Research & Autoimmunity
|
|
Signatures
|
/s/ Misbah Tahir, by power of attorney
|
2024-04-23
|
|
**Signature of Reporting Person
|
Date
|
Explanation of Responses:
|
(*)
|
If the form is filed by more than one reporting person, see Instruction 5(b)(v).
|
|
(**)
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
|
(1)
|
Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
|
|
(2)
|
1/4th of the shares subject to the option vested on October 11, 2022 and 1/48 of the shares subject to the option vest each month thereafter, provided that the Reporting Person remains a service provider through each vesting date.
|
|
(3)
|
1/48th of the shares subject to the option vested on April 12, 2022 and 1/48 of the shares subject to the option vest each month thereafter, provided that the Reporting Person remains a service provider through each vesting date.
|
|
(4)
|
1/48th of the shares subject to the option vested on April 12, 2023 and 1/48 of the shares subject to the option vest each month thereafter, provided that the Reporting Person remains a service provider through each vesting date.
|
|
(5)
|
1/48th of the shares subject to the option vested on April 12, 2024 and 1/48 of the shares subject to the option vest each month thereafter, provided that the Reporting Person remains a service provider through each vesting date.
|
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient,
See Instruction 6 for procedure.Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
